// App-Quantinova.ai

LB1900 : FIRST INTERIM ANALYSIS OF ALPINE STUDY: RESULTS OF A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Researchers

Presenter

  • Peter Hillmen

Principal Investigators

  • Jennifer R. Brown

  • Nicole Lamanna

  • Susan O'Brien

  • Constantine S. Tam

  • Lugui Qiu

  • Maciej Kazmierczak

  • Keshu Zhou

  • Martin imkovic

  • Jiri Mayer

  • Amanda Gillespie-Twardy

  • Mazyar Shadman

  • Alessandra Ferrajoli

  • Peter S. Ganly

  • Robert Weinkove

  • Tommi Salmi

  • Meng Ji

  • Jessica Yecies

  • Kenneth Wu

  • William Novotny

  • Jane Huang

  • Wojciech Jurczak

Medical Centers

  • Department of Haematology, Christchurch Hospital, Christchurch, New Zealand

  • Fred Hutchinson Cancer Research Center, Seattle, WA, United States

  • Department of Hematology and Bone Marrow Transplantation, University of Medical Sciences, Poznan, Poland

  • Chao Family Comprehensive Cancer Center, University of California, Orange, CA

  • University of Melbourne, Parkville, Australia

  • Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

  • Department of Pathology and Biomedical Science,University of Otago,Christchurch,New Zealand

  • BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc.,San Mateo, CA,Vereinigte Staaten

  • Blue Ridge Cancer Care,Roanoke, VA,United States

  • Department of Internal Medicine I, University Hospital Cologne, Cologne,

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

  • Royal Melbourne Hospital, Parkville, Australia

  • Department of Global Health, University of Washington, Seattle, WA, United States

  • Herbert Irving Comprehensive Cancer Center, Columbia University ,New York,Vereinigte Staaten

  • Department of Radiation Oncology, Dana-Farber Cancer Institute Boston MA United States

  • Malaghan Institute of Medical Research,Malaghan Institute of Medical Research, Wellington,New Zealand

  • St. James's University Hospital, Leeds, United Kingdom

  • 4th Department of Internal Medicine - Hematology,University Hospital Hradec Kralove,Hradec Kralove,Rep. Ceca

  • Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Wellington Blood and Cancer Centre, Capital and Coast District Health Board,Wellington,New Zealand

  • First Faculty of Medicine, Charles University, Prague, Czech Republic

  • Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland

  • St Vincent's Hospital, Fitzroy, Australia

Locations

  • New Zealand

  • United States

  • Poland

  • Australia

  • China

  • Germany

  • United Kingdom

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Lymphomas

Biomarkers

  • Tumor protein p53

Drug/Treatment

  • Ibrutinib

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

  • Superiority

  • Non Inferiority

Phase

  • III

Study Id's

  • NCT03734016

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved